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Concurrent with the global increase in obesity,1 numerous 
studies and reviews have been published concerning 
associations of overweight and obesity with mortality. 
Their ﬁ ndings have prompted considerable public health 
debate. There is ongoing discussion as to whether cutoﬀ  
points for body-mass index (BMI) categories should diﬀ er 
across regions or racial or ethnic groups.2 Additionally, 
studies diﬀ er in their assessment of the relation between 
BMI and mortality. In particular, BMI in the overweight 
category (BMI 25–<30 kg/m²) is not consistently associated 
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well as research on primary prevention. Much of the global 
disease burden arises from smoking (about 6·2 million 
deaths and 144 million disability-adjusted life-years 
[DALYs]), excessive salt intake (3·7 million deaths and 74·3 
million DALYs), sugar (0·1 million deaths and 6·2 million 
DALYs), and alcohol (2·8 million deaths and 99·3 million 
DALYs).4 Increasing public awareness of the harms of 
these risk factors could contribute to improved individual 
and community-driven self-management of lifestyle 
behaviours. Reduction of exposure to these risk factors 
at a population level (for example, reducing salt and 
sugar content in processed foods at the manufacturing 
stage) has been shown to be beneﬁ cial for cardiovascular 
disease and overall health.5,6 Compelling evidence shows 
that taxation on these hazardous behavioural factors 
could represent a valuable strategy to improve health.7–11 
Revenue from these taxations could and should be used 
to fund primary preventive programmes and research on 
stroke and other major non-communicable diseases.
A 2012 resolution from the UN has mandated for all 
governments to achieve a 25% reduction in the burden 
from stroke and other non-communicable diseases by 
2025.12 Cost-savings from the reduction of the burden 
of stroke and other non-communicable diseases 
could then be re-invested in health and other social 
programmes to fund primary prevention research and 
develop and implement sustainable evidence-based 
primary prevention strategies in their communities. 
Supported by non-government organisations and the 
health sector, as well as communities, industries, and 
individuals at risk for stroke or non-communicable 
diseases, these preventive programmes could slow 
down, stop, and eventually revert the stroke or non-
communicable disease epidemics.13 We have heard 
the calls for actions about primary prevention. Now is 
the time for governments, health organisations, and 
individuals to proactively reduce the global burden of 
stroke. Governments of all countries should develop and 
implement an emergency action plan for the primary 
prevention of stroke.
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with increased mortality.3,4 To improve precision, 
observational studies have been combined in pooled 
analyses and meta-analyses. Pooled analyses beneﬁ t from 
the use of harmonised methods but, unlike meta-analyses, 
are not generally based on systematic review.
In The Lancet, The Global BMI Mortality Collaboration5 
presents results from the largest ever pooled dataset 
about the relation between BMI and mortality. Their 
data began with 239 studies, in 32 countries, with 
more than 10 million participants and about 1·6 million 
deaths. Prespeciﬁ ed analyses of never smokers without 
pre-existing chronic disease, excluding the ﬁ rst 
5 years of follow-up, are presented for about 3·9 million 
participants and about 386 000 deaths occurring 
in 189 studies. This study is notable for the use of 
standardised methods to extract hazard ratios (HRs) 
for mortality across the studies and for extensive and 
valuable appendices that examine diverse subsets of 
the pooled data. The authors made eﬀ orts to address 
reverse causation and residual confounding. Results are 
broadly similar to other recent studies.3,6,7 For example, 
HRs were J-shaped, with increased risk of mortality 
for both low BMI and obesity (BMI ≥30 kg/m²). This 
study documents heterogeneity in the association 
between BMI and mortality across diﬀ erent continents 
and shows weaker associations in older populations, 
especially in those aged 70 years and older. For 
overweight adults (BMI 25–<30 kg/m²), HRs—adjusting 
for age and sex and excluding individuals with baseline 
chronic disease—ranged from 0·99 (95% CI 0·98–1·00) 
after adjustment for smoking to 1·11 (1·10–1·11) 
after exclusion of ever smokers and the ﬁ rst 5 years of 
follow-up. The elevated HR of 1·11 in overweight adults 
after exclusion of about 60% of the sample and about 
75% of deaths is a key result of this pooled analysis.
Two major issues are raised by this important paper. 
The ﬁ rst is whether conclusions about the relation 
between BMI and mortality from analyses with extensive 
exclusions can be generalisable and unbiased. The second 
is what sort of public health guidance can be obtained 
from analyses that pool global data. Substantial research 
and conceptual questions remain for each of these issues. 
Samples of diﬀ erent distributions of environmental and 
person-speciﬁ c factors (eg, disease history, diet, and 
physical activity) are diﬃ  cult to address consistently in 
large pooling studies. Exclusion of ever smokers, deaths 
in the ﬁ rst 5 years of follow-up, and pre-existing chronic 
disease (where available) might further increase these 
diﬀ erences. Extensive exclusions might also limit the 
generalisability of resulting health recommendations. 
Selection bias and early mortality exclusion, to control for 
potential bias from weight change due to occult disease 
leading to reverse causation, pose additional challenges 
for inference from pooling studies.8 For example, Monte 
Carlo simulation and analytical analyses of the association 
between BMI and mortality indicate that exclusion of 
2 years or 5 years of early mortality does not necessarily 
reduce bias and can even increase bias of estimated HRs.9
Challenges in deriving global public health 
recommendations are unlikely to be resolved by 
ever-larger datasets without further developments 
in study data and design. New study designs such as 
mendelian randomisation,10 new data elements such as 
weight histories,11 and increased attention to BMI over 
the life course,12 might improve our understanding of 
the links between excess bodyweight and mortality. 
The present study compares data from four continents, 
pooling data across diverse racial and ethnic groups, 
and across countries with very diﬀ erent patterns 
of chronic disease management.2 Large studies of 
speciﬁ c race and ethnic groups, such as that of Yi and 
colleagues of 12·8 million Koreans,4 can help to clarify 
recommendations for speciﬁ c countries or demographic 
groups even if these studies cannot conclusively address 
the limits of observational studies.
Despite the limitations of observational studies 
for causal inference of obesity and mortality,13 many 
crucial questions about BMI will continue to rely on 
H
in
du
st
an
 T
im
es
/C
on
tr
ib
ut
or
/G
et
ty
 Im
ag
es
Comment
736 www.thelancet.com   Vol 388   August 20, 2016
Laboratory studies and limited clinical trials over the past 
two decades have shown feasibility and safety, and have 
revealed potential mechanisms of action of stem-cell 
therapy in ischaemic stroke. Despite consistent eﬃ  cacy in 
animal studies, functional beneﬁ ts after transplantation 
of stem cells remain to be shown unequivocally in stroke 
patients.1 Translation of stem-cell therapy from the 
laboratory to the clinic has been approached with ample 
caution, in part due to the largely negative outcomes for 
several stroke therapeutics in human beings compared 
with those in animals. Negative results in clinical trials 
of stem-cell therapy for stroke could put regenerative 
medicine in this area in jeopardy, as for Parkinson’s 
disease when patients given transplanted fetal cells had 
controversial adverse events.2 
Strict adherence to the preclinical ﬁ ndings when 
designing clinical trials might facilitate translation 
of outcomes with stem-cell therapy to the clinic.3 To 
this end, laboratory studies support the concepts of 
neuroprotection for the acute phase of stroke and 
neuroregeneration via stem-cell therapy for the subacute 
and chronic stages.4 Subacute delivery of stem cells is 
designed to sequester early secondary cell death, for 
instance by suppressing oxidative stress, inﬂ ammation, 
Age of PISCES: stem-cell clinical trials in stroke
observational data. To date, few suﬃ  ciently sized 
randomised trials have been done to address whether 
weight-loss interventions reduce mortality or 
morbidity. One trial14 was ended after about 10 years 
of follow-up because no association between weight 
loss and cardiovascular events was found. Weight-
loss interventions have only modest long-term 
eﬀ ectiveness15 and generally target behaviours, such as 
diet and physical activity,13 that can lead to change in 
BMI rather than directly targeting BMI itself. Therefore, 
clinical trials are limited in their capacity to address 
causal relations between BMI and mortality.
Important challenges remain in the eﬀ ort to translate 
epidemiological evidence of excess bodyweight and 
mortality into eﬀ ective guidelines and public health 
interventions. The Lancet, via the World Obesity 
Federation, and other coalitions such as the US National 
Collaborative on Childhood Obesity Research, are 
championing diverse approaches to this challenge 
including support for better measurement, systems 
models, and increased attention to the evaluation of 
obesity-related policies.
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